[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364608-105":59,"doc-detail-364608-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","broad-spectrum-efficacy-of-ceacam6-targeted-antibodydrug-conjugate-with-bet-protein-degrader-in-colorectal-lung-and-breast-cancer-mouse-models","Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models","","Despite advances in antibody–drug conjugates (ADCs), many solid tumors remain difficult to cure, and key challenges persist for ADC use in specific cancer types. This study reports CEACAM6 overexpression across colorectal, lung, and breast cancers and evaluates the broad-spectrum efficacy of the CEACAM6-targeted ADC 84-EBET, carrying a BET protein degrader EBET. In vitro organoid and cell line assays show higher potency versus approved-payload ADCs and standard chemotherapies, while in vivo mouse models demonstrate strong tumor regression, including complete regression in PD-1 antibody-resistant syngeneic settings. Mechanistically, 84-EBET induces bromodomain-containing protein 4 degradation via bystander effects, reduces stromal inflammatory phenotypes, and increases activated T-cell numbers within tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/broad-spectrum-efficacy-of-ceacam6-targeted-antibodydrug-conjugate-with-bet-protein-degrader-in-colorectal-lung-and-breast-cancer-mouse-models/364608/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/broad-spectrum-efficacy-of-ceacam6-targeted-antibodydrug-conjugate-with-bet-protein-degrader-in-colorectal-lung-and-breast-cancer-mouse-models/364608.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is 84-EBET and what does it target?","Question",{"text":112,"@type":113},"84-EBET is a CEACAM6-targeted antibody–drug conjugate designed to deliver the BET protein degrader EBET to tumor and microenvironment contexts.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was 84-EBET evaluated in this study?",{"text":117,"@type":113},"The study used in vitro assays with cancer organoids and cell lines and in vivo mouse models, including patient-derived xenografts and syngeneic models.",{"name":119,"@type":110,"acceptedAnswer":120},"What results support the broad-spectrum efficacy claim?",{"text":121,"@type":113},"In vitro potency exceeded ADCs with approved payloads and standard chemotherapies, and in mouse studies a single injection caused marked regression of colorectal-, lung-, and breast-cancer xenografts, with strong effects even in PD-1 antibody-resistant models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364608,1790198451,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models  \nHiroyuki Kogai1, Shuntaro Tsukamoto1, Minaho Koga1, Masayuki Miyano1, Tsuyoshi Akagi1, Atsumi Yamaguchi1, Kiyoshi Mori2, Kunihito Gotoh3, and Youya Nakazawa1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Despite remarkable advances in cancer treatment, most solid cancers remain difficult to cure. We recently developed an antibody–drug conjugate (ADC; 84-EBET) for pancreatic cancer by using the carcinoembryonic antigen–related cell adhesion molecule 6 (CEACAM6) antibody \\#84.7 and the bromodomain and extra-terminal (BET) protein degrader EBET. In this study, we showed the overexpression of CEACAM6 in colorectal, lung, and breast cancers and the broad-spectrum efficacy of 84-EBETin mouse models of these cancers. In vitro assays using cancer organoids and cell lines of colorectal, lung, and breast cancers revealed that 84-EBET was more potent than ADCs with known approved payloads—DXd, SN38, and monomethyl auristatin E—or standard chemotherapies. In mouse studies, a single injection\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | of 84-EBET induced marked regression of colorectal-, lung-, and breast cancer patient–derived xenograft tumors and cell line– derived xenograft tumors. Moreover, in mouse syngeneic colorectal cancer, lung cancer, and breast cancer models resistant to PD-1 antibody, the combination of 84-EBET and PD-1 antibody induced complete regression of most tumors. Mechanistically, 84-EBET degraded bromodomain-containing protein 4 in both cancer and stromal cells via bystander efficacy. It decreased stromal inflammatory phenotypes and increased activated T-cell numbers in tumors. These results demonstrate that delivering BET protein degraders to tumors and their microenvironments via a CEACAM6-targeted ADC may be effective against a wide range of solid cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nIn the past few years, the high efficacy of antibody–drug conjugates (ADC) has been demonstrated in the treatment of solid tumors such as breast cancer and lung cancer. However, there are still many challenges for ADC use in some cancer types—especially in pancreatic cancer and colorectal cancer—leaving room for improvement with more appropriate targets and payloads. Many ADCs with various targets [EGFR, HER2, human epidermal growth factor receptor 3, trophoblast cell surface antigen 2 (TROP2), and carcinoembryonic antigen–related cell adhesion molecule 5 (CEACAM5)] and with various payloads [DXd, SN38, maytansine, and monomethyl auristatin E (MMAE)] have been examined in clinical trials for colorectal cancer. However, even with the use of the approved trastuzumab DXd (HER2-DXd) and sacituzumab govitecan (TROP2-SN38), the response rates in colorectal cancer have been relatively lower than those i","cbCaiqWlewjGJJE8","https://ap.wps.com/l/cbCaiqWlewjGJJE8","pdf",16335801,14,"English","# Introduction\n## Antibody–drug conjugates and unmet needs in solid tumors\n## Challenges in pancreatic and colorectal cancer\n## Clinical experience with existing ADC targets and payloads\n## Rationale for expanding targets and payloads","[{\"question\":\"What is 84-EBET and what does it target?\",\"answer\":\"84-EBET is a CEACAM6-targeted antibody–drug conjugate designed to deliver the BET protein degrader EBET to tumor and microenvironment contexts.\"},{\"question\":\"How was 84-EBET evaluated in this study?\",\"answer\":\"The study used in vitro assays with cancer organoids and cell lines and in vivo mouse models, including patient-derived xenografts and syngeneic models.\"},{\"question\":\"What results support the broad-spectrum efficacy claim?\",\"answer\":\"In vitro potency exceeded ADCs with approved payloads and standard chemotherapies, and in mouse studies a single injection caused marked regression of colorectal-, lung-, and breast-cancer xenografts, with strong effects even in PD-1 antibody-resistant models.\"}]","Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models | PDF",1790158539,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/929a9e63ba762e9bcb74546d7a47e1ee.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86b74787e4a7bda69b0d91cb4554bf74.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ec820d02962ed9a58455e3679a1331a.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b0c3c6773e936ec558ce4f688f6f168.webp",980,1311]